COMMUNIQUÉS West-GlobeNewswire

TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor with a fully subcutaneous dose regimen
24/10/2025
Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD), 1 , 2 , 3 providing the simplicity of a fully subcutaneous dose regimen in [...]
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
24/10/2025
Achieves significant expansion of NeurAxis’ total addressable market Clearance now includes patients aged “8 years and older” Expanded age indication will utilize the upcoming January 1 st , 2026, Category I CPT code to [...]
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
24/10/2025
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
HealthLynked Launches New MedOfficeDirect Shopify Platform at DiscountOnlineMedicalSupplies.com with Improved Performance and Lower Prices
24/10/2025
NAPLES, Fla., Oct. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ), a leading provider of healthcare technology and patient engagement solutions, today announced the launch of its new [...]
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
24/10/2025
New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged ≥2 years New long-term data demonstrate that ZORYVE cream was well-tolerated and [...]
23andMe Research Institute Names Brad Margus and Stephen Quake, D.Phil., to Board of Directors
24/10/2025
PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, today announced two new members of its Board of Directors. Brad Margus and Stephen Quake, D. [...]
ProPhase Labs to Present at the 2025 ThinkEquity Conference
24/10/2025
UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be [...]
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
24/10/2025
TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ( “ Company” or “ SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat [...]
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
24/10/2025
The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. ( [...]
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
24/10/2025
- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company [...]
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
24/10/2025
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential [...]
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
24/10/2025
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of its [...]
ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
24/10/2025
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results on Friday, November [...]
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
24/10/2025
This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, [...]
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
24/10/2025
MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a [...]
Vistin Pharma ASA: Invitation to Q3 2025 conference call
24/10/2025
Oslo, Norway, 24 October 2025 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2025 results on Friday 31st of October 2025. Vistin Pharma will host a conference call for all shareholders and interested [...]
Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed as its new President
24/10/2025
AMSTERDAM, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Polpharma Group, one of the largest pharmaceutical groups operating across Central and Eastern Europe and Central Asia, announces a planned leadership transition. Effective [...]
Avextra Supports Phase II Clinical Trial in Italy on Cannabis-based medicines for Neurodegenerative Diseases
24/10/2025
First patient enrolled in randomized, placebo-controlled study Bensheim, 24. October 2025 – Neurodegenerative diseases represent one of the biggest challenges of our time. In Germany alone, there are currently around 1. [...]
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
24/10/2025
PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]

Pages